NTRK2 and neoplasm: We utilized an RNA hybrid capture-based NGS approach designed to detect fusions and splice variants in 55 genes including NTRK1, NTRK2, and NTRK3 fusions, resulting in a detection rate of 0.35% across a real-world, pan-tumor cohort.